- Home
- KPLT vs HCWB Comparison
KPLT vs HCWB Comparison
Compare KPLT & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- HCWB
- Stock Information
- Founded
- KPLT 2012
- HCWB 2018
- Country
- KPLT United States
- HCWB United States
- Employees
- KPLT N/A
- HCWB N/A
- Industry
- KPLT Diversified Commercial Services
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- HCWB Health Care
- Exchange
- KPLT Nasdaq
- HCWB Nasdaq
- Market Cap
- KPLT 30.1M
- HCWB 26.6M
- IPO Year
- KPLT N/A
- HCWB 2021
- Fundamental
- Price
- KPLT $8.86
- HCWB $0.34
- Analyst Decision
- KPLT Hold
- HCWB
- Analyst Count
- KPLT 2
- HCWB 0
- Target Price
- KPLT $12.00
- HCWB N/A
- AVG Volume (30 Days)
- KPLT 176.0K
- HCWB 226.8K
- Earning Date
- KPLT 03-13-2025
- HCWB 11-14-2024
- Dividend Yield
- KPLT N/A
- HCWB N/A
- EPS Growth
- KPLT N/A
- HCWB N/A
- EPS
- KPLT N/A
- HCWB N/A
- Revenue
- KPLT $241,789,000.00
- HCWB $3,495,990.00
- Revenue This Year
- KPLT $12.92
- HCWB $229.19
- Revenue Next Year
- KPLT $6.23
- HCWB N/A
- P/E Ratio
- KPLT N/A
- HCWB N/A
- Revenue Growth
- KPLT 14.99
- HCWB 22.27
- 52 Week Low
- KPLT $5.08
- HCWB $0.28
- 52 Week High
- KPLT $23.54
- HCWB $2.52
- Technical
- Relative Strength Index (RSI)
- KPLT 62.11
- HCWB 39.56
- Support Level
- KPLT $6.24
- HCWB $0.33
- Resistance Level
- KPLT $12.14
- HCWB $0.39
- Average True Range (ATR)
- KPLT 1.00
- HCWB 0.05
- MACD
- KPLT 0.33
- HCWB -0.00
- Stochastic Oscillator
- KPLT 44.69
- HCWB 6.54
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.